Ben R. Taft, PhD

Senior Director of Chemistry, Via Nova Therapeutics

Bio

Ben has been working as a medicinal chemist since 2011. After completing his postdoc, he joined Novartis, where he conducted discovery-phase research for oncology indications. While at Novartis, he transitioned to infectious disease drug discovery. He then joined Via Nova Therapeutics, a Novartis antiviral spinout founded by Don Ganem and Kelly Wong, when Novartis exited the infectious disease space.

Drug Discovery
在本期 CAS 系列文章《药物开发的挑战与机遇》中,我们与 Via Nova Therapeutics 的化学高级总监 Ben Taft 讨论了构效关系研究和生物活性数据的潜在前沿。
|Article